AbCellera Biologics Inc.
NMS: ABCLLive Quote
📈 ZcoreAI Score
Our AI model analyzes AbCellera Biologics Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ABCL Z-Score →About AbCellera Biologics Inc.
Healthcare
Biotechnology
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
📊 Fundamental Analysis
AbCellera Biologics Inc. demonstrates a profit margin of -194.9%, which is below the sector average, suggesting competitive pressure.
The company recently reported 788.2% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -14.5%, which indicates that capital utilization is currently under pressure.
At a current price of $3.54, ABCL currently sits at the 35th percentile of its 52-week range (Range: $1.94 - $6.51).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$1.07B
Trailing P/E
--
Forward P/E
-4.52
Beta (5Y)
0.85
52W High
$6.51
52W Low
$1.94
Avg Volume
3.63M
Day High
Day Low